Unit 18 Question Bank
Structure: a nonpolar core of triacylglycerol and cholesteryl ester, surrounded by a surface monolayer of amphipathic phospholipid, free cholesterol and apolipoprotein, whose polar faces contact the aqueous plasma.
Four major classes, in order of increasing density and decreasing size:
• Chylomicrons — from the intestine, carry dietary triacylglycerol, apo B-48
• VLDL — from the liver, carry endogenous triacylglycerol, apo B-100
• LDL — the end product of VLDL catabolism, cholesterol-rich, delivers cholesterol to tissues
• HDL — reverse cholesterol transport, apo A-I, highest protein content (~50%)
Since protein is denser than lipid, the more lipid a particle carries the larger and less dense it is.Harper's ch.25, pp.254–255
Three functions: (1) structural — they hold the particle together and confer solubility; (2) enzyme cofactors; (3) ligands for cell-surface receptors, determining where the particle is delivered.
The principal ones:
• apo B-100 — liver; VLDL, IDL, LDL; the ligand for the LDL receptor
• apo B-48 — intestine; chylomicrons; 48% of the length of B-100, from the same gene by RNA editing, and lacks the receptor-binding domain
• apo A-I — HDL; activates LCAT
• apo C-II — activates lipoprotein lipase
• apo E — mediates hepatic uptake of chylomicron remnants and IDLHarper's ch.25, pp.255–258
It requires apo C-II as an activator and phospholipid as a cofactor; insulin induces its synthesis in adipose tissue, directing fat to storage in the fed state.
Do not confuse it with hormone-sensitive lipase, which is intracellular, releases fatty acids out of the adipocyte, is activated by phosphorylation in response to epinephrine and glucagon, and is inhibited by insulin.
Deficiency causes familial hypertriacylglycerolemia (type I) with chylomicronemia.Harper's ch.25, pp.256, 262–263
Nascent discoidal HDL from liver and intestine takes up free cholesterol from cell membranes via the transporter ABCA1. LCAT, activated by apo A-I, esterifies it using a fatty acid from phosphatidylcholine; the nonpolar ester moves into the core, keeping the surface concentration low so more cholesterol can flow in, and the disc becomes spherical HDL₃ then HDL₂.
The cholesteryl ester returns to the liver either directly, via scavenger receptor B1, or indirectly, transferred by CETP to VLDL and LDL.
This explains the inverse relation between HDL concentration and coronary risk. ABCA1 deficiency = Tangier disease.Harper's ch.25, pp.261–262
Two categories of cause: (1) raised plasma free fatty acids from adipose tissue, as in starvation, diabetes mellitus and high-fat diets; (2) a metabolic block in VLDL production — a block in apolipoprotein synthesis, a failure to provide phospholipid (as in choline deficiency, whose reversal is the lipotropic action), or a failure of the secretory mechanism.
Ethanol causes fatty liver by raising the NADH/NAD⁺ ratio, which inhibits fatty acid oxidation and the citric acid cycle and favours esterification. Prolonged steatosis may progress to fibrosis and cirrhosis.Harper's ch.25, pp.264–265
The problem lipoproteins solve
Lipids are insoluble in water, yet must be moved between organs in an aqueous plasma. The solution is a particle with a nonpolar core of triacylglycerol and cholesteryl ester, wrapped in a surface monolayer of amphipathic phospholipid, free cholesterol and apolipoprotein. Because protein is denser than lipid, the more lipid a particle carries, the larger and the less dense it is — so density and diameter run in opposite directions across the four classes.
| Class | Origin | Main lipid | Main apo | Function |
|---|---|---|---|---|
| Chylomicrons | Intestine | Dietary TAG | B-48, C-II, E | Transport of dietary fat |
| VLDL | Liver | Endogenous TAG | B-100, C-II, E | Export of hepatic fat |
| LDL | From VLDL | Cholesterol | B-100 | Cholesterol to tissues |
| HDL | Liver, intestine | Phospholipid, cholesterol | A-I | Reverse cholesterol transport |
The apolipoproteins do three jobs
They are structural, they act as enzyme cofactors, and they are ligands for receptors. apo C-II activates lipoprotein lipase; apo A-I activates LCAT; apo B-100 binds the LDL receptor; apo E mediates hepatic remnant uptake. apo B-48 is 48% of the length of B-100, transcribed from the same gene and shortened by RNA editing, and it lacks the receptor-binding domain — which is exactly why chylomicron remnants must be cleared through apo E instead.
The exogenous pathway — dietary fat
Dietary triacylglycerol is emulsified by bile salts, hydrolysed by pancreatic lipase with colipase to 2-monoacylglycerol and free fatty acids, and absorbed in mixed micelles. In the enterocyte it is re-esterified by the monoacylglycerol pathway and packaged with apo B-48 into chylomicrons, which enter the lymph, not the portal blood. (Short- and medium-chain fatty acids go straight into the portal blood.)
In the circulation the chylomicron acquires apo C-II and apo E from HDL. Lipoprotein lipase on the capillary endothelium, activated by apo C-II, strips the triacylglycerol; the apo C-II is returned to HDL; and the remnant is taken up by the liver through apo E.
The endogenous pathway — hepatic fat
The liver secretes VLDL carrying apo B-100. Lipoprotein lipase removes its triacylglycerol progressively, forming IDL and then LDL — so LDL is simply the cholesterol-rich residue of a VLDL particle. LDL is taken up by receptor-mediated endocytosis: apo B-100 binds the receptor, the particle clusters in clathrin-coated pits, and lysosomal hydrolysis releases free cholesterol, which inhibits HMG-CoA reductase, suppresses LDL-receptor synthesis and activates ACAT.
Reverse transport — HDL
Nascent discoidal HDL takes up free cholesterol from cell membranes via ABCA1. LCAT, activated by apo A-I, esterifies it; the nonpolar ester sinks into the core, keeping the surface concentration low so more cholesterol can flow in, and the disc rounds into HDL₃ then HDL₂. The cholesteryl ester returns to the liver directly via scavenger receptor B1 or indirectly via CETP. Only the liver can excrete cholesterol, as cholesterol or bile acids in bile.
Clinical correlates
- Familial hypercholesterolemia — defective LDL receptor; raised LDL, premature atherosclerosis.
- Familial lipoprotein lipase deficiency (type I) — chylomicronemia and hypertriacylglycerolemia.
- Abetalipoproteinemia — failure to synthesise apo B; no chylomicrons or VLDL, fatty liver.
- Tangier disease — ABCA1 deficiency; near-absent HDL.
- LDL correlates positively and HDL inversely with coronary risk — because they carry cholesterol in opposite directions.
The balance that is disturbed
The hepatocyte is a busy transit point for fat, and triacylglycerol accumulates whenever the rate at which it arrives or is synthesised exceeds the rate at which it is exported as VLDL or oxidised. Every cause of fatty liver is a disturbance of one side of that balance, and Harper's groups them into two categories.
Category 1 — too much fat arriving
Raised plasma free fatty acids released from adipose tissue overwhelm the liver's export capacity. This occurs in starvation, diabetes mellitus and diets high in fat — all states of low insulin, in which hormone-sensitive lipase is unrestrained. It is accompanied by ketosis, since the same acetyl-CoA surplus drives ketogenesis.
Category 2 — a metabolic block in VLDL production
The liver cannot export what it cannot package. The block may lie at any point in the assembly line:
- A block in apolipoprotein synthesis — no apo B-100, no VLDL. The congenital form is abetalipoproteinemia; toxins such as carbon tetrachloride, chloroform, phosphorus, lead and arsenic and antibiotics such as puromycin produce the same effect acquired. Protein deficiency (kwashiorkor) acts here too.
- A failure to provide phospholipid for the surface monolayer — the classic case is choline deficiency, and the reversal of it is what is meant by the lipotropic action of choline. Essential fatty acid deficiency acts similarly.
- A failure of the secretory mechanism itself.
Ethanol — the important special case
Alcohol dehydrogenase and aldehyde dehydrogenase both generate NADH, so ethanol oxidation raises the NADH/NAD⁺ ratio. This inhibits fatty acid oxidation and the citric acid cycle, both of which require NAD⁺, and so diverts fatty acids into esterification. The same redox shift impairs gluconeogenesis by favouring lactate over pyruvate — hence alcoholic hypoglycemia. Chronically, the microsomal ethanol-oxidising system is induced, and prolonged steatosis may progress to fibrosis and cirrhosis.